Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory Hypersensitivity Pneumonitis
NCT07035561Phase 2Completed
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in hypersensitivity pneumonitis (HP). Started Jun 2023; status: completed.
02
Drugs
rituximab
03
Conditions
hypersensitivity pneumonitis (HP)
Beyond the preview
Go deeper on NCT07035561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035561.